Core Viewpoint - Boya Bio (300294) confirmed that according to the "Blood Product Management Regulations," a single plasma collection station can only supply raw plasma to one blood product manufacturer with which it has signed a quality responsibility agreement, prohibiting supply to any other entities [1] Group 1 - The regulation mandates that the plasma collected by the Green Cross (China) subsidiary must be processed and produced by Green Cross (China) [1]

Core Viewpoint - The company has made significant progress in building its marketing team, commercial channels, and academic promotion system, enhancing its market presence and product delivery capabilities [1] Group 1: Marketing Team Development - The company has established a professional and market-oriented marketing team, which is crucial for its growth strategy [1] Group 2: Academic Promotion - The academic promotion efforts have achieved near-complete coverage of major hospitals nationwide, providing strong support for direct product delivery to end-users [1] Group 3: Commercial Channel Development - The company has formed strong alliances with mainstream commercial entities, creating complementary advantages that enhance its market position [1]

Group 1 - The company is focused on industry development trends and strategic opportunities that enhance its core competitiveness and create long-term value [1] - The company acknowledges that external mergers and acquisitions carry significant uncertainty [1] - Currently, the company has no plans for related mergers and acquisitions [1]

证券代码：300294 证券简称：博雅生物 公告编号：2026-002 华润博雅生物制药集团股份有限公司 | 是否为 | 是 | | | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 控股股 | 是否为 | 否 | 质 | 股 | 质 | | | | | | | | | | | | 东或第 | 本次质 | 占其所 | 占公司 | 限售股 | 为 | 质押 | 押 | 东 | 质权 | 押 | | | | | | | 一大股 | 押数量 | 持股份 | 总股本 | （如是， | 补 | 起始 | 到 | 名 | 人 | 用 | | | | | | | 东及其 | (股) | 比例 | 比例 | 注明限 | 充 | 日 | 期 | 称 | 途 | | | | | | | | 一致行 | 售类型） | 质 | 日 | | | | | | | | | | | | | | 动人 | 押 | 苏州 | | | | | | ...

Core Viewpoint - The company, Boya Biological, emphasizes its position as a cash-intensive blood product manufacturer with a long production cycle, highlighting the importance of inventory management strategies in response to various influencing factors [1] Group 1: Company Operations - The company acknowledges that inventory turnover is affected by multiple factors including industry characteristics, market supply and demand, and regulatory policies [1] - The company plans to align its product production schedule with its raw plasma supply scale to ensure adequate market supply and maintain reasonable inventory levels [1] Group 2: Inventory Management Strategy - The company intends to develop a comprehensive inventory management strategy that considers the aforementioned factors to optimize its operations [1]

Core Viewpoint - The company is implementing a "one product, one strategy" sales approach to enhance business and organizational restructuring, aiming to improve operational efficiency and solidify its academic brand management system [1] Group 1 - The company is advancing business and organizational restructuring [1] - The company is exploring a refined招商模式 (refined recruitment model) to enhance operational efficiency [1] - The company aims to strengthen and solidify its academic brand through a closed-loop management system [1] Group 2 - The company is ensuring reasonable inventory levels for its products [1]

Group 1 - The company, Boya Bio-Pharmaceutical, is characterized as a blood product enterprise with high cash payment requirements and long production cycles [1] - The company plans to strictly regulate its product production schedule based on its raw plasma scale to ensure market supply and maintain reasonable inventory levels [1]

（文章来源：证券日报） 证券日报网讯 1月13日，博雅生物在互动平台回答投资者提问时表示，公司2026年1月9日含信用账户合 并名册的股东人数为30763户。 ...

Core Insights - The article highlights significant developments in China's private equity and venture capital landscape, focusing on various funds established to support innovation and technology sectors [5]. Government-Backed Funds - The Bank of China launched a 600 billion yuan initiative to support key technology sectors, with 100 billion yuan allocated for equity investments and 500 billion yuan for credit financing [7]. - The Zhejiang Social Security Science and Technology Fund has completed registration with an initial scale of 500 billion yuan, targeting industries like AI and biomedicine [8]. - The Hebei Jin Capital Fund was established with a total scale of 32 billion yuan, focusing on high-end materials and new energy sectors [8]. Regional Investment Funds - The Hengqin Guangdong-Macao Deep Cooperation Zone Fund increased its scale from 10 billion yuan to 30 billion yuan, achieving a 7.89% annualized return [9]. - The Fujian (Xiamen) Social Security Science and Technology Fund has officially launched with a scale of 20 billion yuan, focusing on AI and advanced manufacturing [9]. - The Jiangsu Province has set up a 50 billion yuan AI special fund to promote AI development [10]. Private Equity and Venture Capital Developments - The Beijing Jingguo Fund was established with a scale of 4 billion yuan, focusing on private equity investments [15]. - The Abu Dhabi Investment Authority led a $770 million follow-on fund for CDH Fund V, indicating continued interest in Chinese assets [16]. - The "Puchuang Huazhang" direct investment fund was launched with a scale of 500 million yuan, targeting strategic emerging industries [16]. Sector-Specific Funds - The Huazhong University of Science and Technology established a 3 billion yuan fund for biomanufacturing projects [13]. - The Hainan Free Trade Port Construction Investment Fund doubled its capital to 200 billion yuan, focusing on high-tech and strategic industries [18]. - The China Southern Power Grid's fund reached 14 billion yuan, emphasizing carbon neutrality investments [18]. Emerging Trends - The article notes a growing trend of collaboration between private and public sectors to enhance investment in technology and innovation [5]. - There is a notable increase in funds targeting AI, biomedicine, and advanced manufacturing, reflecting a strategic shift towards high-tech industries [9][10][18].

Group 1 - The core viewpoint of the news is that Boya Bio's stock performance and financing activities indicate a mixed outlook, with significant financing activity but a decline in net profit year-over-year [1][2]. - On January 9, Boya Bio's stock rose by 0.82%, with a trading volume of 110 million yuan. The financing buy-in amount was 17.34 million yuan, while the financing repayment was 35.24 million yuan, resulting in a net financing outflow of 17.89 million yuan [1]. - As of January 9, the total balance of margin trading for Boya Bio was 685 million yuan, with a financing balance of 683 million yuan, accounting for 5.76% of the circulating market value, indicating a high level compared to the past year [1]. Group 2 - As of December 31, Boya Bio had 30,100 shareholders, a slight decrease of 0.03% from the previous period, while the average circulating shares per person increased by 0.03% to 16,737 shares [2]. - For the period from January to September 2025, Boya Bio reported a revenue of 1.474 billion yuan, representing a year-over-year growth of 18.38%. However, the net profit attributable to the parent company was 343 million yuan, reflecting a year-over-year decrease of 16.90% [2]. - Boya Bio has distributed a total of 1.007 billion yuan in dividends since its A-share listing, with 489 million yuan distributed over the past three years [3].